Therapeutic Area | MeSH |
---|---|
neoplasms | D009369 |
skin and connective tissue diseases | D017437 |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
TEMODAR | Merck & Co | N-022277 RX | 2009-02-27 | 1 products, RLD, RS |
Brand Name | Status | Last Update |
---|---|---|
temodar | New Drug Application | 2024-10-30 |
temozolomide | ANDA | 2025-01-09 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
glioblastoma | EFO_0000515 | D005909 | — |
melanoma | — | D008545 | — |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Glioblastoma | D005909 | EFO_0000515 | — | 232 | 299 | 63 | 4 | 62 | 557 |
Glioma | D005910 | EFO_0000520 | — | 95 | 121 | 17 | 2 | 25 | 224 |
Neoplasms | D009369 | — | C80 | 82 | 66 | 5 | 1 | 2 | 130 |
Central nervous system neoplasms | D016543 | — | — | 46 | 69 | 11 | 1 | 7 | 119 |
Brain neoplasms | D001932 | EFO_0003833 | C71 | 53 | 62 | 11 | 1 | 11 | 118 |
Astrocytoma | D001254 | EFO_0000271 | — | 41 | 36 | 16 | 1 | 9 | 93 |
Neuroblastoma | D009447 | EFO_0000621 | — | 22 | 32 | 2 | 1 | — | 47 |
Oligodendroglioma | D009837 | EFO_0000631 | — | 16 | 20 | 5 | 1 | 2 | 42 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Nervous system neoplasms | D009423 | — | — | 44 | 62 | 11 | — | 7 | 110 |
Melanoma | D008545 | — | — | 36 | 68 | 15 | — | 1 | 98 |
Gliosarcoma | D018316 | — | — | 41 | 46 | 7 | — | — | 78 |
Recurrence | D012008 | — | — | 37 | 39 | 5 | — | 6 | 75 |
Sarcoma | D012509 | — | — | 17 | 24 | 2 | — | 2 | 40 |
Lymphoma | D008223 | — | C85.9 | 10 | 20 | 1 | — | 4 | 32 |
Lung neoplasms | D008175 | — | C34.90 | 7 | 27 | 3 | — | 2 | 31 |
Neoplasm metastasis | D009362 | EFO_0009708 | — | 11 | 20 | 2 | — | 2 | 30 |
Neuroendocrine tumors | D018358 | EFO_1001901 | D3A.8 | 5 | 24 | 2 | — | 1 | 29 |
Medulloblastoma | D008527 | — | — | 15 | 15 | 1 | — | — | 26 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Carcinoma | D002277 | — | C80.0 | 6 | 15 | — | — | — | 18 |
Breast neoplasms | D001943 | EFO_0003869 | C50 | 5 | 13 | — | — | 1 | 17 |
Colorectal neoplasms | D015179 | — | — | 5 | 11 | — | — | — | 14 |
Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 6 | 8 | — | — | — | 12 |
Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 3 | 8 | — | — | — | 9 |
Neuroendocrine carcinoma | D018278 | — | — | 1 | 8 | — | — | — | 9 |
Pinealoma | D010871 | — | — | 5 | 4 | — | — | — | 8 |
Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 6 | 2 | — | — | — | 7 |
Kidney neoplasms | D007680 | EFO_0003865 | C64 | 6 | 2 | — | — | — | 7 |
Uveal neoplasms | D014604 | EFO_1001230 | — | 1 | 6 | — | — | — | 6 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Meningioma | D008579 | EFO_0003098 | D32.9 | 5 | — | — | — | — | 5 |
Craniopharyngioma | D003397 | — | — | 4 | — | — | — | — | 4 |
Adamantinoma | D050398 | — | — | 4 | — | — | — | — | 4 |
Lymphopenia | D008231 | — | D72.810 | 2 | — | — | — | — | 2 |
Mesothelioma | D008654 | — | C45 | 2 | — | — | — | — | 2 |
Thymus neoplasms | D013953 | — | C37 | 2 | — | — | — | — | 2 |
Brain diseases | D001927 | — | G93.40 | 2 | — | — | — | — | 2 |
Phenylketonurias | D010661 | — | E70.0 | 2 | — | — | — | — | 2 |
Malignant mesothelioma | D000086002 | — | — | 1 | — | — | — | — | 1 |
Urinary bladder neoplasms | D001749 | — | C67 | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Chemoradiotherapy | D059248 | — | — | — | — | — | — | 1 | 1 |
Maximum tolerated dose | D020714 | — | — | — | — | — | — | 1 | 1 |
Intensity-modulated radiotherapy | D050397 | — | — | — | — | — | — | 1 | 1 |
Residual neoplasm | D018365 | — | — | — | — | — | — | 1 | 1 |
Depression | D003863 | — | F33.9 | — | — | — | — | 1 | 1 |
Infertility | D007246 | EFO_0000545 | — | — | — | — | — | 1 | 1 |
Genetic variation | D014644 | EFO_0004828 | — | — | — | — | — | 1 | 1 |
Drug common name | Temozolomide |
INN | temozolomide |
Description | Temozolomide is an imidazotetrazine that is 3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine which is substituted at positions 3, 4, and 8 by methyl, oxo, and carboxamide groups, respectively. A prodrug for MTIC (5-(3-methyltriaz-1-en-1-yl)-1H-imidazole-4-carboxamide, formed by spontaneous hydrolysis of temozolomide in the body), it is used as an oral alkylating agent for the treatment of newly diagnosed malignant glioblastoma multiforme (concomitantly with radiotherapy) and malignant melanoma. It has a role as an antineoplastic agent, a prodrug and an alkylating agent. It is an imidazotetrazine, a monocarboxylic acid amide and a triazene derivative. |
Classification | Small molecule |
Drug class | — |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | Cn1nnc2c(C(N)=O)ncn2c1=O |
PDB | — |
CAS-ID | 85622-93-1 |
RxCUI | — |
ChEMBL ID | CHEMBL810 |
ChEBI ID | 72564 |
PubChem CID | 5394 |
DrugBank | DB00853 |
UNII ID | YF1K15M17Y (ChemIDplus, GSRS) |